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ABSTRACT

This research provides ultrastructural information
regarding pulmonary surfactant secretion from stimulation of
adrenergic pathways to the lung via the stellate ganglion.
This information will help clarify the important role of the
sympathetic nervous system in surfactant disorders.

It also

provides insight into sympathetic mechanisms causing
surfactant derangement in adult and infant respiratory
distress syndromes

(RDS).

Basic cellular mechanisms of

surfactant metabolism, including synthesis and packaging in
lamellar bodies, were studied.

Results shed light on these

basic processes of lung cell function.
The results of this study provide new avenues for
studying a problem in health care that has long resisted
advances, that of surfactant replacement therapy.

It is

expected that the results of this research, taken with
information from other researchers, will ultimately reduce
the 50% mortality rate of the 150,000 patients annually
suffering from RDS

(Andreadis and Petty 1985).
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INTRODUCTION

Discovery of Surfactant

The concept of a surface active material in the lungs
has interested physiologists for over 40 years.

In 1929,

von Neergaard demonstrated the effects of surface forces on
the pressure-volume characteristics of excised lungs and
speculated that the surface tension of alveolar fluid might
be decreased to below that commonly found for other
biological fluids

(von Neergaard 1929).

Although many have

since repeated von Neergaard's simple experiment, the
magnitude of this effect was not fully appreciated for three
decades.

Pattle

(1958)

and Clements and co-workers

(1958)

showed that alveolar lung fluid forms an insoluble film at
an air-liquid interface and modifies the surface tension of
this interface in a manner which depends on alveolar surface
area.

Recently it has been advocated that surfactant should

be considered to act not only as a detergent role by
locating at air-aqueous interfaces and reducing surface
tensions, but in modifying solid surfaces to which it is
absorbed

(Hills and Bryan-Brown 1983).
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Alveolar Type II Cells
The synthesis and secretion of pulmonary surfactant is
initiated in fetal lung tissue during the latter stages of
gestation (Comroe 1974).

As the type II cell differentiates

in late gestation, cell size decreases, glycogen is greatly
depleted, and lamellar bodies, the hallmark of the type II
cell, appear in the cytoplasm (Williams and Mason 1977).
Vidic and Burri

(1981)

showed in a study using the rat type

II pneumonocyte that not only subcellular components but the
type II cell as a whole undergoes quantitative changes in
early postnatal life.
Alveolar type II cells are usually situated in the
alveolar niche between capillaries.

The cells are roughly

cuboidal in shape and provided with irregular short
microvilli on their free surface.

The cells are tightly

attached to the adjacent squamous epithelial cells.

The

most striking feature of these cells is the presence of
characteristic lamellar inclusion bodies.

The lamellar

bodies store surfactant and secrete their content into the
alveolar lumen by an exocytosis process, stimulated by
alveolar expansion, beta adrenergic mechanisms
Rieutort 1987)

(Bourbon and

and with possible involvement of microtubules

(Stratton 1976).
Once outside the cell, lamellar bodies unfold to form
tubular myelin, a unique physical form of surface active
material that on cross-section appears as a lattice formed
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from adjoined rectangular tubes.

It is generally considered

as a transition form between packaged surfactant and the
functional monolayer lining, which subsequently spreads over
the alveolar surface.

Tubular myelin contains lipids

similar to those in surface active material, and Gil and
Reiss

(1973) have suggested that calcium is involved in its

formation.

Finally, tubular myelin is adsorbed to the air-

liquid interface to form the surface film.
The main functions of type II cells are synthesis and
secretion of pulmonary surface active material.

A

second

major function of type II cells is to regenerate a
continuous epithelium after diffuse alveolar injury.

Type

II cells may secrete substances other than surface active
material, such as enzymes, but the functions of these
enzymes are not known

(Mason et al. 1977).

A final

postulated function of the type II cells is control of the
electrolyte composition of the alveolar subphase, a very
thin aqueous layer between alveolar epithelial cells and the
air-liquid interface.

Mason and Williams

(1977) were the

first to directly demonstrate fluid and electrolyte
transport by alveolar epithelial cells, concluding that
alveolar epithelial cells .have the ability to transport
fluid from the alveolar subphase into the interstitium.
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Surface Tension
References to alveolar surface tension are common in
the physiological and clinical literature today, and most
investigators are willing to accept the validity of a
specialized material called pulmonary surfactant.

Most

agree that pulmonary surfactant phospholipid is synthesized
in, stored in, and released from alveolar type II cells
(Dobbs and Mason 1979).

After birth, the secreted

surfactant lines the alveolus and reduces surface tension at
the air-liquid interface.
Surface tension is a manifestation of attracting forces
between atoms or molecules.

Surface tension has the units

of force per unit of length, and the units of surface
tension are dynes per centimeter.

At 37 degrees centigrade,

pure water has a surface tension of 70 dynes per centimeter;
blood plasma and most tissue fluids at equilibrium have a
surface tension of 50 dynes per centimeter

(Comroe 1974).

Assuming that the alveolar film exerts a surface
tension of 50 dynes per centimeter, calculations would
indicate that the surface tension recoil of the lung would
be 20,000 dynes per square centimeter and would exert a
pressure of about 20 centimeters water.

This calculated

value is five to ten times too large at usual or low lung
volumes.

The surface tension of the alveolar film at small

lung volumes must then be five to ten dynes per centimeter
instead of 50 dynes per centimeter.

This lead Clements
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(1958)

to suspect that the surface tension in the lung fluid

is high when the lungs are inflated and very low when they
are deflated.

This could occur only if the alveolar lining

were something other than saline or ordinary tissue fluid;
it must contain a special type of surface active material.
Several early experimental observations influenced the
methodology that has been used to purify surfactant.
Clements

(1958) obtained materials from the lungs by

repeated rinsing of the airways and airspaces to study this
surface active material, or surfactant.

The surface was

compressed to mimic compression of the alveolar - lining
during expiration, and then expanded, to mimic its expansion
during inspiration.

The results were remarkable.

The

surface tension rose to 40-50 dynes per centimeter when the
film was expanded, and dropped nearly to zero when the film
was compressed.
An alveolus with a low surface tension requires a low
air pressure to maintain a given radius or volume; one with
a high surface tension requires a large counter-pressure.
Low surface tension, therefore, reduces the muscular effort
necessary to ventilate the lungs and keep them aerated.
Surfactant helps to stabilize the alveolar gas bubbles
and keep them from collapsing.

Without some special system

to prevent it, the lung would empty its smaller air spaces
into larger ones and would then consist only of collapsed
alveoli and hyperinflated alveolar ducts.

This does not
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occur in healthy lung because the surface tension of the
alveolar lining is considerably less than that of plasma and
i~ lower than predicted, and the surface tension of the
alveolar lining decreases markedly as the film is
compressed.

This factor,

in conjunction with elastic

elements of the tissue, is sufficient to ensure the
stability and prevent the collapse of small alveoli during
expiration and lead to a stable balance between small and
large alveoli.
When Avery and Mead

(1959)

found that immature fetal

lungs and the collapsed lungs of newborn babies dead of
respiratory distress syndrome
disease

(HMD)

(RDS) or hyaline membrane

contained no surfactant, this material became

a substance of great medical as well as physiologic
importance.

As a result, many investigators have now

studied the chemical and biological characteristics of
pulmonary surfactant.

Composition of Surfactant

Pulmonary surfactant was originally thought to be only
a saturated lecithin, dipalmitoyl phosphatidylcholine.
is now known to be a complex lipoprotein, like those in
membranes but unique in i.ts high concentration of
dipalmitoyl phosphatidylcholine and its protein.

It
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Glycerophospholipid
Approximately 80-85% by weight of surfactant is
glycerophospholipid

(Mendelson et al. 1986); the major

glycerophospholipids of surfactant are disaturated
phosphatidylcholines

(DSPC).

Of the known components, the

saturated phosphatidylcholines give the lowest values of
surface tension and the most stable films on compression.
This accounts for the property unique to lung extracts of
lowering surface tension of compressed films almost to zero.
It is thought that dipalmitoyl phosphatidylcholine
functions as the principle molecular component of the
surface active material in the pulmonary alveoli and that it
bears the brunt of setting up closely-packed, stable surface
films which can withstand high compression, and in this way
give low values for surface tension in the alveoli.

Because

it has unsuitable physical properties for adsorption, it
would be an ineffective surfactant if secreted in pure form.
Clements and co-workers

(Ville 1973) think that it is

complexed with other materials such as apoprotein,
unsaturated phospholipids and neutral lipids which enable it
to form a film rapidly.
Synthesis of DSPC is directly dependent upon a supply
of palmitate from either fetal circulation or from de nova
pulmonary synthesis.

Patterson and co-workers

(1986)

investigated how de nova fatty acid synthesis is controlled
during the critical time of surfactant production and how
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certain lipogenic processes are related by determining
specific short- and long-term effects of key substrates
(lactate and glucose)

and hormones

glucagon and experimental cAMP)

(dexamethasone, insulin,

on fatty acid and surfactant

lipid synthesis in fetal lung.
Results provided evidence that metabolic regulation of
fatty acid synthesis in lung is different from other
lipogenic tissues and that surfactant lipid production is
linked to fatty acid synthesis.

The most likely explanation

of this relationship is that many hormonal effects on DSPC
synthesis may occur via a primary effect on fatty acid
synthesis which serves as an important regulator of
surfactant production.
The phosphatidylglycerol in surfactant has received
much recent attention.

This phospholipid is in relatively

low concentration in surfactant compared with the
phosphatidylcholines, but is high when compared with other
mammalian tissues

(King 1982).

varies with species.

Its fatty acid composition

It is highly enriched in saturated

fatty acids in rat lamellar bodies and lavage fluid but
contains mostly unsaturated fatty acids in these same
fractions isolated from rabbit lung.
Phosphatidylglycerol appears in fetal lung fluids at
about the same time as there occurs a surge in the content
of saturated phosphatidylcholine

(Hallman and Gluck 1977).

When phosphatidylglycerol is present with other surfactant
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lipids, in the presence of calcium, these lipids interact
with the major protein in surfactant to form a large
molecular weight complex.

This lipid-protein comple :: more

readily adsorbs and spreads at an air-liquid interface than
do the lipids themselves.

Protein
Approximately 5-10% of surfactant is protein (Mendelson
et al. 1986).

Several proteins are found in surfactant

derived from alveolar lavage fluid.

The protein most

extensively studied has a molecular weight of 3.5-4.0 x 10
to the fourth power, when measured under conditions that
reduce sulfhydryl bonds

(King 1974) and is probably

specifically associated with surfactant (Clements and King
1976).

It is likely that only alveolar epithelial type II

cells synthesize this protein, and its presence in alveolar
macrophages derives from phagocytic ingestion.

A smaller

protein (or proteins) of about 10 to the fourth power in
molecular weight is also present in alveolar surfactant.
The functions of the apoproteins of surfactant remain
uncertain.

The proteins may be enzymes involved in

glycerophospholipid synthesis and/or degradation.

The

proteins may also serve a structural role in the packaging
of surfactant glycerophospholipid within the type II cell
and/or in the formation of tubular myelin, an inactive form
of surfactant, within the alveolar lumen.

It has also been
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suggested that the proteins may alter the physiochemical
properties of surfactant by enhancing the rate of diffusion
of surfactant glycerophospholipids over the alveolar surface
(Mendelson et al. 1986).

Cholesterol
Intraalveolar cholesterol, another component of
surfactant, may also be worth examining considering reports
emphasizing the importance of cholesterol in normal
surfactant production

(Crittenden and Beckman 1984).

Cholesterol may facilitate DSPC surface adsorption by aiding
surface reentry and dispersion of DSPC molecules over the
aqueous subphase.

King

(1974)

found that cholesterol and

the monoenoic phosphatidylcholines give surface active
material increased molecular mobility and influence its
rate of adsorption to the alveolar interface.

Cholesterol

may also enhance the rate and magnitude of rapid, reversible
surface area changes of the DSPC film as it alternates
between expanded and compressed states at low and high
surface pressures.

These properties of cholesterol could

possibly influence lung function and might be reflected in
measurements of compliance.
A recent study was done by Crittenden and Beckman
(1984) who wished to investigate adrenergic neural
mechanisms involved in the release and removal of
cholesterol and DSPC by using alpha and beta adrenergic
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blocking drugs in combination with stellate ganglion
stimulation.

Their results provided new evidence that

cholesterol secretion into alveolar spaces is influenced by
beta adrenergic pathways.

Furthermore, their finding of

increased DSPC in vivo with direct neural stimulation is
consistent with previous data from pharmacologic studies
implicating beta adrenergic mediation of DSPC secretion.

It

would appear that adrenergic neural activity is an important
mediator in the maintenance of a normal cholesterol/DSPC
ratio which in turn may affect lung surface properties and
function.

Factors Affecting Surfactant Release

Sympathetic Nerve Stimulation
Biochemical analysis of lung lavage indicates that
various forms of sympathetic activation can influence
release of surface active phosphatidylcholine into the
alveolar airspace.

These factors include exercise

(Notter

et al. 1982), hyperventilation (Kobayashi et al. 1978), beta
adrenergic agonists

(Dobbs and Mason 1979) and stellate

ganglion stimulation (Crittenden and Beckman 1984).

While

etiology and basic mechanisms of adult and infant RDS are
unclear, the sympathetic nervous system appears to be an
important influence on both
Rooney 1981).

(Beckman et al. 1971; Marino and
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Sympathetic stimulation has been shown to play a major
role in the development of acute pulmonary injury associated
with mechanical central nervous system damage, surgical
trauma, and severe non-specific stress

(Ducker 1968).

Similar findings in animals exposed to stellate ganglion
stimulation suggest that, in addition to possible
hemodynamic changes, the sympathetics may alter the alveolar
surfactants prior to the subsequent development of pulmonary
congestion and edema

(Beckman and Mason 1973).

Experiments were carried out in a study by Droste and
Beckman

(1974)

to determine what effect prolonged continuous

sympathetic nerve stimulation in cats might have on lung
compliance and lung weight/body weight ratios.

Their

results indicated that a three hour continuous electrical
stimulation of the stellate ganglion decreased lung
compliance by 38% in the absence of any increase in lung
weight/body weight ratio or lung wet weight/dry weight
ratio.

Such evidence suggests that this sympathetic-induced

compliance decrease was due to factors other than
cardiovascular.
Another study addressing the effects of stellate
ganglion stimulation was done by Crittenden and Beckman
(1980)

to determine diameters of alveolar ducts in

spontaneously breathing cats under ketamine anesthesia.
Examination of the outer two millimeters of the lungs by
light microscopy revealed no alveolar duct constriction by
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stellate ganglion stimulation, although compliance was
decreased by 15%.

Pulmonary resistance was unchanged.

Absence of alveolar duct constriction suggests that
peripheral airway constriction did not contribute to the
decrease in compliance during stellate ganglion stimulation.
A more recent study was done by Crittenden and Beckman
(1984)

in order to differentiate between airway smooth

muscle

(dynamic)

effects and tissue elastic recoil

(static)

effects in producing the compliance decrease in stellate
ganglion stimulation.

Pressure-volume relationships were

measured in situ in cats.

The results of this study showed

that stellate ganglion stimulation in cats reduced static
lung compliance only at high lung volumes.

Since stellate

ganglion stimulation may differentially accelerate removal
of cholesterol, and possibly protein and other adsorptionactive components, i t may thereby inhibit the return of DSPC
molecules to the air-liquid interface as the lung expands.
Under these conditions surface tension would increase and
compliance decrease in several breaths, as found in this
study.
Stimulation of the sympathetic nerves in isolated
perfused lungs leads to an increase in pulmonary vascular
resistance and a decrease . in pulmonary vascular compliance
(Ingram et al. 1968).

The pulmonary vasoconstriction

during sympathetic nerve stimulation and norepinephrine
infusion is most prominent on the arterial side of the
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vascular bed .

In addition to these pulmonary hemodynamic

effects , sympathetic nerve stimulation decreases airway
resistance and plays a role in surfactant turnover

(Beckman

et al . 1974) .
It is not as well understood what the effects of
sympathetic stimulation on lung fluid exchange may be.
There may be alterations in transvascular fluid filtration
secondary to pulmonary vasoconstriction, and the associated
change in the microvascular hydrostatic pressure.

A

pulmonary edema that is rich in protein has been produced
with large doses of epinephrine, suggesting a role for
catecholamines in increasing the lung vascular permeability
to proteins

(Theodore and Robin 1976).

Because of the circumstantial evidence suggesting a
role of sympathetic mechanisms in lung transvascular fluid
and protein fluxes, Hakim and co-workers

(1979) undertook a

study to examine the effects of sympathetic nerve
stimulation on fluid and protein exchange in intact sheep
lungs.

They found that stellate ganglion stimulation

resulted in increases in lung lymph flow rate, lymph protein
flux, and protein clearance that were dependent on the
stimulus strength, whereas the lymph-to-plasma protein
concentration ratios remained unchanged.
The finding that the alpha adrenergic blocking agent
phentolamine blunted the increases in lung lymph flow,
protein clearance and protein flux during sympathetic

lymph
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stimulation suggests that alpha adrenergic mechanisms were
involved in the increase in lung vascular permeability.

The

finding that continuous sympathetic nerve stimulation
resulted in increased protein transport across pulmonary
microvessels is consistent with the observation that
intracranial hypertension leads to increased permeability in
sheep (Malik et al. 1979).
In conclusion, the sustained sympathetic nerve
stimulation as produced by stimulating the stellate ganglion
resulted in increases in lung lymph flow and in the net
protein flux and clearance across pulmonary microvessels.
The results suggest a sympathetic-mediated increase in lung
vascular permeability to proteins, and that alpha adrenergic
activation plays a role in mediating the increase in lung
vascular permeability.
The mechanisms of responses of sympathetic nerves to
hypoxia and hypercapnia and to other respiratory stimuli are
not well understood.

The role of chemoreceptors in the

regulation of cervical preganglionic sympathetic nerve
activity was studied by Matsumoto and co-workers
anesthetized and spontaneously breathing cats.

(PSN)

(1987)

in

The study

was undertaken to fill the gaps in current knowledge
regarding PSN responses to respiratory stimuli and their
relationship with carotid chemoreflexes.
It was found that transection of carotid sinus nerves
did not eliminate the PSN responses to transient changes in
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and steady-state levels of hypoxia and hypercapnia, although
it did eliminate the responses to brief stimulation and
inhibition of arterial chemoreceptors by pharmacologic
agents.

The physiological meaning of the observations is

that there are tissues other than peripheral chemoreceptors
which can generate responses of sympathetic nervous system
to a physiological range of hypoxic stimulus and which can
elicit sympathetic control of physiological function,
as organ blood flow,

such

independent of peripheral

chemoreceptors.

Glucocorticoids
Glucocorticoids are considered to serve an important
regulatory role in the synthesis of surfactant
glycerophospholipids by fetal lung tissue.

Abundant

evidence has been presented to demonstrate that accelerated
lung epithelial cell maturation and precocious production of
lamellar bodies accompany the prenatal administration of
glucocorticoids to mammalian fetuses.

Several studies

suggest steroid hormones affect the amount of surfactant
phospholipids in adult lung as well, though the effects have
not been as striking or consistent as those demonstrated in
premature lungs

(Kotas and Avery 1971; Liggins 1969; Wang et

al. 1971).
A recent study was undertaken by Young and Silbajoris
(1986)

to determine the effects of dexamethasone, a
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glucocorticoid, on adult rat lung subcellular lipid
profiles.

They hoped to resolve the uncertainties regarding

the response of the adult lung surfactant system to
glucocorticoids.

They used morphometric and biochemical

techniques to assess the steroid effects.
The researchers concluded that glucocorticoids alter
lamellar body and lavage lipid content in adult rat lungs.
The lamellar body effect is likely due to an increased
phospholipid content per lamellar body.

These data are

consistent with two earlier observations reported by the
same researchers.

In 1982, Young and Silbajoris

(1982)

found a larger lipid pool in lamellar body fractions after
oxygen-induced stress in rats that could be accounted for by
morphometric estimates, and suggested that lamellar body
composition could have been altered during the oxidant
stress.

More recently

(1985), they had found that the

stress of surgical implantation of osmotic minipumps
increased the lavage lipid pool, an effect independent of
beta agonists and antagonists.
Sosenko and co-workers

(1986) undertook a recent study

to determine whether the antioxidant enzymes, like
surfactant, might be regulated in part by an endogenous
glucocorticoid mechanisme

Metyrapone was injected into

pregnant rats three days before delivery.

Metyrapone is an

adrenal 11-beta hydroxylase inhibitor which crosses the
placenta and blocks endogenous glucocorticoid synthesis.
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Significant decreases in lung tissue DSPC and
DSPC/total phospholipids were demonstrated during the final
two days of gestation following maternal metyrapone
treatment.

These results are in agreement with earlier

studies with this agent showing altered surfactant levels or
function in rabbits

(Vidyasgar and Cherwick 1975), baboons

(Kling and Kotas 1975)

and guinea pigs

(Nelson et al. 1976).

This study has demonstrated for the first time a parallel
delay following metyrapone in a nonsurfactant-related
biochemical system in fetal lung, the antioxidant enzyme
system.
The maturational pattern of the antioxidant system and
the surfactant system in fetal lung is remarkably simi~ar.
The biochemical results suggest that human infants with
delayed surfactant development which may be related at least
in part to low glucocorticoid levels, may have delayed
development of their antioxidant system as well, and may
demonstrate intolerance to high oxygen in addition to
hyaline membrane disease if delivered too prematurely.

Adrenergic Effects
The regulation and secretion of surfactant has been
shown to be affected by beta adrenergic agonists

(Brown and

Longmore 1981; Oyarzun and Clements 1978) probably acting
through cAMP

(Mason and Dobbs 1980).

Although there are

some reports that cholinergic agonists may modulate the
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secretion of surfactant, they are probably eliciting the
beta adrenergic system.

The parameters of ventilation

influence the turnover of alveolar surfactant (Oyarzun and
Clements 1977), suggesting that the amount of extracellular
surfactant is controlled in response to changes in
respiratory activity.
surfactant metabolism

Prostaglandins may also affect
(Oyarzun and Clements 1978) but the

contribution of prostaglandins to the overall regulation is
unknown.

Crittenden and Beckman (1984) have shown that beta

adrenergic pathways influence cholesterol secretion into
alveolar spaces.
The adrenergic axis has been implicated in both
surfactant and lung water regulation.

Although there is

considerable evidence regarding the effect of exogenously
administered sympathomimetics on both surfactant production
and release and lung water clearance, the role of endogenous
catecholamines in these processes is not well defined
(Lawson et al. 1979).

McDonald and co-workers

(1986)

examined this issue by blocking beta adrenergic receptors of
the rabbit fetus in vivo with an irreversible beta blocker,
brornacetylalphenolomethane

(BrAlp).

They determined the

effect of beta blockade on phosphatidylcholine content in
lung tissue and lavage fluid and on lung water clearance
from alveolar spaces.
Results demonstrated that the administration of a beta
blocker can decrease the amount of surfactant

(measured as
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phospholipid)

recoverable by lung lavage.

Although there is

a statistically significant reduction in alveolar surfactant
after beta blockade, the degree of reduction may not be
biologically significant at that stage of fetal maturity.
These data indicate that endogenous catecholamines play a
role in surfactant secretion in both the fetal and newborn
rabbit.
found,

No effects of BrAlp treatment on lung water were
suggesting perhaps a less important role of

endogenous catecholamines or that few receptors are required
for this response than remained after treatment.

It is

likely that the adrenergic system is just one of several
interacting systems that influence surfactant production and
release at the time of birth.

Chlorphentermine
Another drug used in experimental studies is
chlorphentermine.

It is an anorexic agent, and one of a

group of cationic amphiphilic drugs which produces a
phospholipid storage disorder in the lungs of laboratory
animals.

The most striking changes in the lungs are an

increase in the number of alveolar macrophages and
particulate debris in the alveoli.
mechanism(s)

Although the basic

responsible for the drug-induced

phospholipidosis remains unknown, there is some evidence to
indicate that phospholipid degradation is impaired
al. 19 8 6) .

(Miles et
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Surfactant Removal and Reuptake

Little is known of chemical or physical factors that
inactivate surfactant or remove it once it is spread on the
alveolar surface.
recycled;

Some may reenter alveolar cells and be

some may enter the "liquid veins" between alveoli

and pass into lymphatics; some may be engulfed by alveolar
macrophages.

Some have postulated that cigarette smoking

increases the number of alveolar macrophages and so
increases the rate of surfactant removal

(Comroe 1974).

The reuptake of surfactant phospholipids by the
epithelium has been demonstrated in vivo by disappearance of
phospholipid liposomes instilled into the airways

(Jacobs et

al. 1984; Oyarzun et al. 1980) and in vitro through
accumulation of exogenous phospholipids in lung slices and
isolated type II cells

(Claypool et al. 1984).

Some

researchers demonstrated that increased ventilation results
in an increased rate of clearance of phospholipids from the
alveolar space, suggesting that reuptake may be
physiologically regulated.

Furthermore, since

hyperventilation also increases surfactant secretion,
reuptake may be linked with secretion in order to regulate
the extracellular concentration of this material.

Beta

adrenergic mediators also stimulate surfactant phospholipid
secretion

(Massaro et al. 1982), but their affect on
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clearance of phospholipids from the alveolar space has not
been evaluated.
In a recent study, Fisher and co-workers

(1985) used

the isolated perfused rat lung for determination of
phospholipid clearance from the airspaces and then evaluated
the effects of beta adrenergic agonists on this process.
The results suggest that the retention of exogenous
phospholipid by the isolated perfused rat lung represents
phospholipid uptake and that the process is under beta
adrenergic control.

They concluded that secretion and

uptake may be physiologically linked to regulate the
concentration of surfactant on the alveolar surface.
There is also evidence that the lung can be depleted of
surfactant when lung volume is decreased or very large
(Comroe 1974).

When the lung is deliberately ventilated

with low tidal volumes beginning near residual volume, it
tends to become atelectatic and needs a new surface film
with each inspiration.

This is because a film, once

collapsed, does not spread out again when stretched unless
new molecules enter its surface.

When a lung is

deliberately overstretched, return to functional residual
capacity can also promote film collapse~
Large tidal volumes require additional surfactant.

On

the other hand, the process of film collapse occurs much
more slowly in static lungs than in lungs tidally
ventilated.

Since lung collapse, overdistention and large
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tidal volumes appear to increase the requirement for new
surfactant, i t appears that, when slight differences are
critical, the best way to maintain balance between loss and
gain of surfactant molecules is to maintain a relatively
high transpulmonary pressure and permit normal tidal volumes
on this basis.

This is the rationale for treating babies

with RDS with continuous positive airway pressure.

This new

therapy has strikingly reduced mortality in babies born with
this disorder.

Infant and Adult Respiratory Distress Syndrome

In 1959, Avery and Mead

(1959)

reported that extracts

of lungs from infants who died from RDS were deficient in
surfactant, that is, they had abnormal surface tensionlowering characteristics as compared with extracts from
lungs of newborns who had died of nonpulmonary causes.

Much

has been learned since then about the etiology,
pathophysiology and treatment of this disease

(Farrel 1982).

The role of surfactant abnormalities in adult RDS
is not known.

Because of the heterogeneity of causes, it is

difficult to infer a common pathogenetic mechanism in the
development of this syndrome

(Haagsman and Van Golde 1985).

There is some evidence, however, to suggest that surfactant
lipids are deficient or altered in patients with adult RDS
(Hallman et al. 1982).

The role of altered breathing
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patterns and fever,

if present, must also be evaluated

(Massaro 1981; Massaro et al. 1981).
There are many similarities between adult RDS and the
RDS of premature newborn infants, including increased liquid
content of the lungs with a normal pulmonary capillary wedge
pressure

(noncardiogenic pulmonary edema), alveolar

collapse, ventilation-perfusion imbalance, right to left
shunting of blood, decreased compliance and the development
of hyaline membranes.

Therefore, some investigators have

suggested that adult RDS might result from defective
surfactant synthesis

(Petty and Ashbaugh 1971).

The extent to which surfactant is compromised in other
pulmonary diseases such as alveolar proteinosis, oxygen
toxicity, and perhaps others, is still speculative.

The

recent findings suggesting that metabolic changes may occur
in the surfactant system in adult RDS provide impetus to
explore this question in other diseases

(King 1982).

Clearly, more work needs to be done before the mechanisms
of atelectasis and reduced lung compliance present in
patients with adult RDS are elucidated.

Fatty Acid Composition
Shelley and co-workers

(1979) reported that surfactant

from premature infants with HMD shows a pattern in
phosphatidylcholine fatty acid composition that is
distinctly different from that of a control group of
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premature infants with mature lung formation.

They observed

a decreased compliment of palmitic acid (16:0), with an
increase in oleic acid

(18:1).

normal as recovery occurs.

The pattern becomes more

A similar change has been

observed during in utero lung development
1967).

(Brumley et al.

Thus, fetal lung maturation is accompanied by

qualitative, as well as the more generally recognized
quantitative, changes in the pulmonary surfactant.

Appearance of Phosphatidylglycerol
and Phosphatidylinositol
The appearance of phosphatidylglycerol in the tracheal
wash of infants with HMD has been reported to be associated
with clinical signs of recovery.
(1986)

Jackson and co-workers

tested the hypothesis that recovery from experimental

HMD begins only after an increase in the synthesis and
secretion of phospholipid rich in the surfactants
phosphatidylglycerol and DSPC.

In order to examine the

recovery process _in HMD in vivo methods not feasible in
humans, the researchers have previously studied nonhuman
primates with experimental HMD

(Jackson et al. 1985).

The

observations that deflatiort stability improved over the
first 12 hours of life even though total lung capacity
declined and remained low for the first two days caused the
researchers to investigate the timing and role of surfactant
synthesis and secretion in the recovery process.
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Compared to 140-day fetuses, the healthy controls had a
several-fold increase in lavage phospholipid and DSPC during
the first few days of life.

Prior to recovery, animals with

HMD had no such increase in lavage phospholipid or DSPC and
demonstrated poor deflation stability.

Recovery was

associated with increased tissue and lavage phospholipid and
increased fractions of phosphatidylinositol and DSPC but not
phosphatidylglycerol.

The tissue compositional changes

observed during recovery reflected maturational changes
observed in the fetal animals studied at ten days greater
gestational age.

The authors conclude that increases in

DSPC and phosphatidylinositol are associated with recovery
from HMD but phosphatidylglycerol does not appear necessary
for either improved deflation stability or clinical
recovery.
A similar finding with regard to phosphatidylglycerol
was found by Liau and co-workers

(1985).

In a study of

isolated lungs from bronchioalveolar lavage of dogs, they
found that phosphatidylglycerol may not be a critical
determinant of lung surfactant function and that its
specific role in the surfactant may be assumed by
phosphatidylinositol.

Surfactant Inhibitory Activity
RDS, besides being characterized by volume loss and
decreased compliance, is also associated with pulmonary
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edema, bronchiolar epithelium destruction, and a leak of
plasma proteins into the airways and alveoli
1983; Nilsson et al. 1978; Said et al. 1965).

(Jobe et al.
The alveolar

pulmonary edema may inactivate surfactant in vivo since
plasma proteins can inhibit surfactant function in vitro
(Jobe et al. 1983).
To further characterize the effect of surfactant
inhibition by proteinaceous pulmonary edema, Berry and coworkers

(1986)

used the model of bilateral cervical vagotomy

in adult rabbits.

Respiratory distress in the vagotomy

rabbits was characterized by a marked decrease in lung
compliance, an increase in alveolar-arterial oxygen
gradient and atelectasis and results at least in part from
surfactant dysfunction caused by the proteinaceous pulmonary
edema.

This phenomenon of surfactant inhibition by plasma

proteins is consistent with findings in RDS and supports the
authors' belief that inhibitory activity plays an important
role in this disease.

This disruption of surfactant

function can be partially overcome by a treatment with
natural surfactant.
Another study addressing surfactant inhibitory activity
was carried out by Ikegami and co-workers

(1986).

They

wondered whether a protein inhibitor could be isolated from
cord blood, amniotic fluid and airway samples from infants
with RDS and whether the quantity of airway-associated
inhibitor might correlate with disease severity.

This
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inhibitor presumably appears in the alveoli because of the
abnormal protein leak present in the lungs of infants with
RDS.
Inhibitor protein was found in serum and amniotic fluid
of both infants with RDS and normal infants.

The

researchers presumed the inhibitor protein is a normal serum
component that can incidentally disrupt surfactant surface
properties when i t enters the alveoli.

Their results are

consistent with the concept that the inhibitor contributes
to surfactant dysfunction and thus the respiratory failure
characteristic of RDS.
Rice and Singleton

(1985) demonstrated marked

inhibit~on of surfactant secretion from isolated type II
cells by the polyamines.

Since inhibition of surfactant

secretion appears to be mediated by small polybasic
compounds, Rice and Singleton (1986) undertook a study to
test the hypothesis that substance P regulates surfactant
secretion in isolated type II cells.
Substance Pis an undecapeptide.

This neuropeptide is

distributed throughout the central and peripheral nervous
system as well as the gastrointestinal tract, and has also
been recently identified in lung tissues
Lazarus et al. 1983).

(Barnes 1984;

The function of these neuropeptides

in lung is unclear at the present time.
The results of the present study demonstrate inhibition
of

[3H]

phosphatidylcholine secretion by substance P.

This
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supports the hypothesis that amino-terminal basic groups of
substance Pare necessary for inhibition of surfactant
secretion from isolated type II cells and support the
concept that an inhibitory system contributes to mediation
of surfactant secretion from type II epithelial cells.

Surfactant Replacement

Substitution Therapy
Many advances have been made in the care of newborn
infants with RDS.

Nevertheless, this disease remains an

important cause of mortality and morbidity in the low birth
weight infant.

Surfactant substitution is a promising way

to treat or prevent RDS

(Enhorning and Robertson 1972;

Fujiwara et al. 1980) and would be of benefit in these
infants.

Surfactant TA
Early attempts to replace surfactant in infants with
RDS were unsuccessful due to incomplete knowledge of
surfactant composition and improper delivery methods
et al. 1984).

Recently Fujiwara and co-workers

(Gitlin

(1980) have

treated newborn infants with RDS using a well-characterized
organic solvent extract of beef lung surfactant (surfactant
TA).

A dramatic decrease in the oxygen requirement was

demonstrated in these infants within three hours after
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treatment.

Promising results have also been shown by

Enhorning and co-workers

(1985) using a bovine surfactant

and by Hallman and co-workers

(1985) using huQan surfactant

isolated from term amniotic fluid.
In a more recent study, Hallman and co-workers

(1986)

attempted to analyze the quality, quantity and turnover of
surfactant phospholipids among the small preterm infants who
received natural homologous surfactant in a randomized trial
to treat severe RDS.

The control infants tended to have

lower saturated phosphatidylcholine/sphingomyelin ratios
during the first week than the surfactant-treated infants.
The recipients of surfactant had slightly more serious lung
disease than the controls when the results were adjusted by
covariance to remove the differences in the saturated
phosphatidylcholine/sphingomyelin ratio.

Exogenous

surfactant increased the apparent endogenous pool size at
least five-fold.

The half life was independent of the

amount of exogenous surfactant.
previous data

Clearly, the present and

(Jobe et al. 1983; Stewart-DeHann et al. 1980)

. contradict the possibility that exogenous surfactant in RDS
inhibits endogenous synthesis and secretion.
Gitlin and co-workers

(1987) undertook a study most

recently to critically assess the role of surfactant
replacement in the treatment of HMD.

They used a well-

characterized bovine surfactant preparation (surfactant TA)
that has the potential of becoming widely available and is
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free of human pathogens

(Fujiwara et al. 1979; 1980).

The

findings from this study demonstrate that surfactant TA
given early in the course of severe HMD leads to a prompt
and sustained improvement in oxygenation and a decrease in
the need for ventilatory support.

Surfactant TA may offer

an advantage over human and other currently available
exogenous surfactants in its potential for wide
availability, quality control, and demonstrated efficacy.
Nevertheless, long-term studies will be needed to ensure the
safety of TA surfactant, especially in view of potential
immunologic effects from bovine-derived material.
A recent study by Ikegami and co-workers

(1987)

compared natural sheep surfactant, rabbit surfactant, human
surfactant and surfactant TA for in vitro surface properties
and for responses of preterm lambs to treatment.

Although

all surfactants were superior to no treatment in these very
preterm surfactant-deficient lambs, surfactant TA, the
surfactant with the best in vitro properties based on
standard criteria, was not the best surfactant when tested
in vivo in the premature lamb.
The authors suggested that in vitro surface properties
as presently used to develop surfactants for clinical use
will not accurately predict in vivo responses because of
present poorly understood interactions of different
surfactants with the preterm lung.

Once several surfactants

are available for clinical use, they will need to be
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directly compared in clinical trials to establish which
preparation is the most effective.
Animal or human surfactant extracts placed into the
trachea at birth or when respiratory failure develops have
been shown to improve the oxygenation of premature babies
and thus reduce the incidence of severe complications.

In a

University of Illinois study (1987), 30 neonates with birth
weights of 751 to 1750 grams and severe hyaline membrane
disease received a single dose of reconstituted bovine
surfactant within six hours of birth.

Three of the 17

babies treated died, compared with seven of 13 who received
placebo,

Pneumothorax and pulmonary interstitial emphysema

were more common in the placebo group, while hemodynamically
significant patent ductus arteriosis (PDA) was seen more
frequently in the treated babies.

The authors note that

because five placebo deaths occurred sooner than the age at
which clinical signs of PDA are usually manifest, the PDA
incidence was undercounted in the placebo group.
Although in animal subjects better results were
obtained when surfactant was instilled at birth, the authors
recommend that use of bovine surfactant be restricted to
infants with established lung disease or lung immaturity.
As they point out, not all premature or low-birth-weight
infants will develop hyaline membrane disease.
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Current Research Rationale

Other investigators have used ultrastructural methods
to evaluate the secretory response of alveolar type II cells
to exogenous catecholamines
et al. 1982) .

(Massaro and Massaro 1983; Smith

Among other advantages, this approach allows

direct examination of the type II cell.

Increased

surfactant in lung lavage from sympathetic nerve stimulated
cats has provided additional support for a direct neural
influence on type II cells.
Cats will be used in this research because in this
species the stellate ganglion is easy to find
retropleurally.

The retropleural approach is crucial due to

the necessity of keeping the chest and pleural space intact
to preserve functional integrity as closely as possible.
Other small laboratory species are unsuitable due to lack of
stellate ganglion.
The cat also has the largest stellate ganglion of any
species, comprising the fused inferior cervical ganglion and
the first four thoracic ganglia.

Thus the cat is a more

appropriate model for studying sympathetic effects of
stellate ganglion stimulation on the lung, because the third
and fourth ganglia supply the pulmonary plexus

(Crouch

1969).
The diseases of infant and adult RDS have been rather
resistant to improvement and care

(Bone 1984), and it is now
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apparant that merely supplying replacement surfactant
components to the lungs' airway does not always restore lung
compliance.

With a few notable exceptions

Tanaka et al. 1986)

(Jobe 1986;

surfactant replacement therapy does not

appear to have widespread clinical usage.

The solution to

the problem, therefore, is to be found by understanding
basic mechanisms of these surfactant deficiency syndromes.
One of those basic mechanisms involves understanding the
type II cells that secrete surfactant (Freiherr 1985).

The

present research addresses this problem and it is hoped that
the results, taken with information from other researchers
studying basic mechanisms of surfactant release and
activation, will ultimately reduce the 50% mortality rate of
RDS sufferers

(Andreadis and Petty 1985).

The studies mentioned indicate conflicting evidence
regarding surfactant metabolism, therefore, the present
study was undertaken in order to further define the role of
the sympathetic nervous system in surfactant release.
Ultimately, knowledge regarding surfactant release and
activation will be immensely important to health care
personnel dealing with infant and adult RDS.

METHODS AND MATERIALS

Animals

Tissue for this thesis research was obtained from
experimental cats.

These cats were previously treated with

stellate ganglion stimulation as described below.
Sixteen cats

(Pearcroft Farms, Beaufort, NC)

anesthetized with ketamine

(Ketalar, Parke-Davis, Atlanta,

GA) were ventilated in the supine position for 30 minutes
with 100% oxygen via tracheal cannula.

The right stellate

ganglion of four control and four experimental cats was
exposed retropleurally via an incision through the skin and
muscle layers under the scapula.

In control cats the

ganglion was not manipulated any further.

In stellate

stimulated cats an electrode was placed on the ganglion in
order to provide an electrical stimulus.
After an appropriate time interval, each cat was
disconnected from the ventilator and the chest opened with a
midline incision.

The lungs were allowed to collapse for 60

seconds to ensure complete degassing.
Karnovsky's)

Fixative

(modified

perfused the vasculature at a pressure of 20

centimeters water via an incision in the right ventricle
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(Callas 1974).

The left atrium was cut to allow escape of

the pulmonary perfusate.

At the same time, fixative was

infused into the lungs via the tracheal cannula at a
pressure of 20 centimeters water.
continued for 30 minutes.

The perfusion was

After 30 minutes one cubic

millimeter blocks of lung tissue were removed from the
middle right lobe and put into cold fixative identical to
the perfusate for an additional two hours.

Tissue cubes

were then post fixed in one percent osmium tetroxide in
0.1 M phosphate buffer for an additional two hours,
dehydrated in a series of ethanol and propylene oxide, and
embedded in Polybed 812 embedding plastic

(Polysciences,

PA).
Thin

(60-80 nanometer)

sections were obtained from

embedded tissue blocks using a Reichart OM-2 ultramicrotome.
Sections were stained with uranyl acetate and lead citrate
and examined in a Hitachi HS8-2 transmission electron
microscope.

Ultrastructural features were observed and

micrographs were taken of type II cells which exhibited
microvilli and cuboidal epithelium.

Sympathetic Stimulation Principles

In order to produce neurally mediated sympathetic
activation of parenchymal lung tissue, in four cats the
exposed stellate ganglion was stimulated with a wire
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electrode connected to a Grass S-44 stimulator
Puerto Rico).

(Hato Rey,

The electrode delivered seven volts at a

frequency of ten pulses per second and duration of ten
milliseconds.

These parameters have been determined to be

least likely to produce stiffening of pulmonary vessels
(Ingram et al. 1968) while providing sympathetic activation
of the parenchyma.
six minutes.

The stellate ganglion was stimulated for

This time interval seemed to provide the

greatest visualization of ultrastructural changes from SGS.

Morphologic Analysis

In order to analyze morphological changes in alveolar
type II lining cells of cats receiving stellate ganglion
stimulation, prints developed from electron micrograph
negatives were enlarged to 10,000 times or larger on
8 X 10 inch photographic paper and observed.
Electron micrographs of lung tissue from stellate
stimulated cats were compared to micrographs of lungs of
normal controls.

Careful attention was paid to appearance

of type II cells in lungs from control versus SGS cats.
Specifically, lamellar inclusion bodies were of interest
and were examined for relative numbers and disposition
throughout the cytoplasm of the type II cell.

Also

examined were the basement membranes of epithelial and
endothelial cells in order to confirm that these membranes
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remained fused.

In addition, mitochondria and microvilli

of type II cells were examined.

Observation was also

made of contractile interstitial elements.

The appearance

of thin squamous type I epithelium was also observed.

RESULTS

Lung tissue from four sham treated control cats was
compared to lung tissue from four stellate stimulated cats.
Over 100 micrographs of 10,000x magnification were studied.
Ultrastructural examination of alveolar morphology by TEM
revealed a consistant decrease of lamellar bodies in
alveolar type II cells of sympathetically stimulated cats.
This is evidenced by comparison of type II cells in Figures
1 and 2.

Figure 1 illustrates the usual abundance of

lamellar bodies in type II cytoplasm of control tissue.
Figure 2, a micrograph of lung tissue from SGS cats, shows
relatively fewer lamellar bodies contained within the cell
cytoplasm.

Some type II cells from SGS cats contained no

lamellar bodies.

These two micrographs are representative

of the majority of control and SGS lung tissue,
respectively.
Large oval vacuolated areas occurred within the
cytoplasm of the type II cells of both control and stellate
tissue.

These vacuoles occurred with similar frequency in

the type II cells of control and SGS cats.

Vacuoles seemed

to be found more frequently in the basal portions of the
type II cells rather than apical.
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Figure 1.

Representative type II cell profile from control
cat.
Note abundance of lamellar bodies (LB)
relative to cytoplasm volume.
Note presence of
vacuolated inclusions (V) similar in size and
shape to lamellar bodies.
Base of cell is
indicated by arrows showing basement membrane
(X8800) .

Figure 2.

Representative type II cell profile from SGS cat.
Cell contains relatively few lamellar bodies (LB)
compared to Figure 1 control tissue.
Note
presence of vacuolated inclusions (V).
Base of
cell is indicated by arrows showing basement
membranes (Xll,500).
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Figure 3 shows typical lamellar inclusion bodies.

The

osmiophilic lamellae in each inclusion body were unaltered
by SGS.

Lamellar bodies did not exhibit any change in size

with SGS.
Numer0us mitochondria were observed and seen with equal
frequency in control and SGS cats

(Figure 4).

Although

distinct cell membranes were observed, cristae were poorly
visualized in most cases.

The interior of most mitochondria

was homogenous and dark in appearance.
Type II cells were easily identified by the appearance
of microvilli

(Figure 5).

There were no differences noted

between control and SGS tissue with respect to size, number
or general appearance of microvilli.
Figure 6 shows the thinness of the squamous type I
epithelium and capillary endothelium.

No nuclei of type I

cells were noted in over 100 micrographs of lung tissue.
Note the profusion of pinocytotic vesicles in capillary
endothelium contrasted with relatively few vesicles in type
I epithelium.
Basement membranes showed fused basal laminae of
alveolar epithelium and capillary endothelium (Figure 6).
The basement membranes remained intact and fused, and were
not affected by the stimulation.

None of the micrographs

indicated separation of the fused membranes or infiltration
of fluid into the interstitium between membranes.

Figure 3.

Examples of lamellar inclusion bodies.
Note
abundance of osmiophilic material, or lamellae,
in each inclusion body.
This type II cell is
from a control cat (Xl3,400).

Figure 4.

Example of mitochondria (M) in type II cell.
Note cristae within the mitochondria.
Stellate
stimulation did not appear to alter the
mitochondria (X7150).

Figure 5.

Example of microvilli lining characteristic of
type II cell.
The microvilli are located at the
air-blood barrier (X8600).

Figure 6.

Representative squamous type I epithelium (Ep).
Note absence of nuclei.
Example of basement
membrane (B) showing how basal laminae of type I
epithelial and capillary endothelial cells are
fused.
Note that membranes show no indication of
separation and that pinocytotic vesicles (P) are
plentiful in the cell cytoplasm (Xll,000).
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Macrophages were easily differentiated from alveolar
type II cells by the fact that the macrophages were
completely free in the alveolar airspace and shared no
basement membrane with the alveolar wall (Figure 7).
Macrophages occasionally contained inclusions resembling
lamellar bodies.

Long cytoplasmic processes projected from

the peripheral cytoplasm.
Contractile interstitial elements as described by
Kapanci and co-workers
(Figure 8).

(1976) were present in some sections

These elements are made up of collagenous

fibrils and elastic fibers.

Appearance of these elements

did not seem to be related to SGS, as they were observed
with equal frequency in both control and SGS cats.
Membranes of cells containing contractile elements were not
easily identifiable, and the cells appeared to be very
irregular.
The monolayer of surfactant covering alveolar surfaces
in life was absent in all micrographs.

This finding most

likely reflects destruction of lipid by the aldehyde in the
modified Karnovsky's solution employed in tissue fixation.
Thus information regarding disposition of this surfactant
layer over the alveolar surface in control versus SGS cats
was not available.
Glycogen granules were not observed in type II cells of
these mature control or SGS cats in any micrographs.

This

finding is consistent with disappearance of these granules
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with maturity (Kikkawa et al. 1968, 1971; Sorokin 1961;
Williams and Mason 1977).

Figure 7.

Representative macrophage completely free in the
alveolar space.
Note cytoplasmic processes (CP)
projecting from peripheral cytoplasm (X6700).

Figure 8.

Contractile interstitial elements (CE) made up of
collagenous fibrils and elastic fibers in the
interstitium of the alveolar region.
Elements
that appear as dots represent cross-sections of
the contractile fibers (Xl0,750).

DISCUSSION

The most important data generated by this thesis
research were the morphologic changes observed with the
transmission electron microscope (TEM).

The most

significant event was depletion of surfactant stores from
alveolar type II cells of SGS cats.

TEM showed fewer

lamellar bodies per type II cell of SGS cats visually
compared to control cats.

It is well established that

depletion of secretory granules from secreting cells is
indicative of increased secretion.
In comparing Figures 1 and 2, it is evident that the
control type II cell contains a greater number of lamellar
bodies.

This is consistent with biochemical data

suggesting sympathetic control of phospholipid secretion
(Brown · and Longmore 1981; Crittenden and Beckman 1984;
Dobbs and Mason 1979; Mason and Dobbs 1980; Massaro et al.
1981; Oyarzun and Clements 1977, 1978; Young and
Silbajouris 1985).

Although observations of these

micrographs suggested depletion of intracellular
surfactant, the process of extrusion was not observed.
This is in contrast to frequent observations by Smith and
co-workers

(1979) of lamellar bodies in the process of
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being secreted into the alveolar space in pilocarpine
treated rabbit fetuses near term.

Massaro and co-workers

(1981) have correlated biochemical evidence of
phospholipid secretion with ultrastructural documentation
of lamellar body depletion in response to the beta agonist
isoproterenol.
Based on objective observation of altered lamellar
body content from SGS, this thesis research provided
further support for a nerve link between the sympathetic
nervous system and alveolar type II cell surfactant
secretion.

Investigation of the role played by neural

innervation in mediating lamellar body depletion is
discussed in reports describing nerve endings near type II
cells in alveolar walls of mouse lungs (Meyrick and Reid
1971; Hung et al. 1973).

These nerve endings are dense

cored, suggestive of motor (stimulatory) function
al. 1973).

(Hung et

The possibility of neural innervation of type

II cells has been directly implicated by a study of
surfactant release during exercise (Nicholas et al. 1982).
Shepard and co-workers
data on excised dog lungs.

(1982) reported morphometric
They evaluated the impact of

alterations in ventilation, substrate availability,
alveolar carbon dioxide tension, hydrogen ion and
bicarbonate concentrations, and temperature and neural
denervation on the lamellar body volume density of type II
cells.

Their data suggest that alveolar hypercapnia via
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its effect in reducing bicarbonate concentration appears
to be the major environmental factor mediating the
depletion of lamellar bodies from type II cells.

This

process was temperature dependent and did not require the
presence of intact neural innervation.
It is unclear what factors control the secretion of
pulmonary surface active material from alveolar type II
cells.

Various researchers have suggested that

cholinergic stimuli, adrenergic stimuli and prostaglandins
may all stimulate secretion (Mason and Dobbs 1980; Oyarzun
and Clements 1978).

Wyszogrodski and co-workers

(1974)

showed that injections of isoxsuprine to 28 day old rabbit
fetuses three hours before delivery increased the lung
stability of the rabbits after delivery.

They felt that

this increase in stability might be the result of an
increase in the amount of alveolar surface active
material.

Olsen (1972) found that isoproterenol, in a

single injection to a rat, caused a decrease in the number
of lamellar bodies per type II "cell profile" and an
increase in the phospholipid content in lung lavages; ~his
effect could be blocked by propranolol.

This

ultrastructural thesis research confirms Olsen's findings
by also showing lamellar body depletion.
Dobbs and Mason (1979) have shown that isolated
alveolar type II cells release DSPC in response to beta
adrenergic stimulation.

It is likely that secretion of
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surface active material in vivo is modulated by beta
adrenergic mechanisms acting directly on type II cells.
Resulti obtained by Crittenden and Beckman (1984) with
alpha blockade and SGS provide evidence that nerve
stimulation also may increase lavage DSPC through beta
receptors.

There is thus reasonable evidence that beta

adrenergic stimulation can increase the release of
components of lung surfactant.
The time course used for the release of surfactant in
this thesis research was six minutes.

This time interval

seemed to provide the greatest assurance of visualization
of ultrastructural changes from SGS.
(1979)

Dobbs and Mason

showed a 50% increase over basal levels of DSPC

release within 15 minutes of administration of the beta
agonist terbutaline to isolated rat type II cells in
culture.

Oyarzun and Clements (1978) found a 43% increase

in DSPC recovered in lung wash following administration of
terbutaline via the pulmonary artery in rabbits.
(1972)

Olsen

found increased phospholipid and depleted type II

cell lamellar bodies in lungs of rats given isoproterenol
30 minutes prior to sacrifice.

The isolated perfused rat

lung was used by Nicholas and co-workers
the effect of a deep breath.

(1982) to examine

Following 30 minutes of

normal ventilation, a large breath increased the amount of
alveolar surfactant phospholipids within 30 seconds.

The
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deep breath also resulted in an increase in oxygen
diffusing capacity.
In their study of the effects of dexamethasone on
surfactant, Young and Silbajouris (1986) obtained results
from adult rats.

Vidic and Burri (1981) studied

quantita~ive changes in the rat type II cell during late
postnatal development.

Their results showed a ten-fold

increase in volume density of lamellar bodies compared to
those reported by Young and Silbajouris (1986).
Lamellar body volume density reported with dogs
(Shepard et al. 1982) exceeded numbers obtained using
adult

(Young and Silbajouris 1986) and postnatal rats

(Vidic and Burri 1981).

Although there appears to be an

increase in morphometric data with larger animals, the
difference between postnatal and adult type II cells, at
least in rats, exhibits a much greater increase.
Mitochondria at one time were considered the
intracellular precursors of lamellar inclusion bodies
(Klaus et al. 1962).

Later researchers found that this is

not the case partly because increased surfactant in fetal
lungs paralleled the increase in type II lamellar bodies
but not in mitochondria.

The present thesis results are

consistent with the view that lamellar body depletion is
not related to mitochondrial changes, because changes in
morphology or cytoplasmic density of mitochondria were not
seen in lamellar body-depleted SGS lung tissue.

In no
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micrographs were there any cristae seen in lamellar
bodies, nor were any osmiophilic lamellae seen in
mitochondria.

In fact, cristae were rarely seen in

mitochondria.

These thesis results support the now

generally accepted conclusion that lamellar bodies are
separate and distinct organelles from mitochondria.
Type I epithelium exhibited no changes with SGS.

No

nuclei or glycogen were observed in the numerous
micrographs studied.
The integrity of the basement membranes was not
affected indicating that SGS effects were manifested
elsewhere in parenchymal lung tissue.

Other areas

affected may include type II cells, contractile
interstitial elements, lung lymph flow, and possibly other
sites.
Macrophages observed often exhibited long cytoplasmic
processes projecting from the peripheral cytoplasm.

In

general, nuclei were spherical in shape with some
indentation, although more irregularly shaped nuclei were
also seen.

The presence of occasional lamellar body-like

structures in the macrophages was most likely the result
of phagocytosis

(Clements and King 1976).

Occasionally

the content of lysosomes within macrophages reveals a
myelin figure

(Ebe and Kobayashi 1972).

Vacuoles were present in some of the type II cells
observed.

They appeared to be about the same size and
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shape of lamellar bodies and their locations within the
cell were similar, but they contained no lamellae.
appeared near the base of the cell.

Most

Their presence may

indicate areas that were washed out by the series of
alcohol dehydrations that were used in preparing the
tissue for TEM.

Kikkawa and co-workers (1986) concluded

that these vacuolated inclusions represented areas of
surfactant secretion.
Contractile interstitial elements were observed
frequently in the interstitium of the alveolar region in
both SGS and control cats.

During ordinary breathing, the

elastic fibers do not undergo much linear extension.
Their role is to serve as protection against shock to the
extensible collagenous fibers if some of them should
rupture during coughing or sneezing (Kapanci et al. 1976).
SGS did not seem to alter the contractile elements with
respect to frequency of appearance in control and SGS
cats.

This thesis research did not specifically examine

the influence of sympathetic stimulation on contraction of
interstitial elements.

However, interstitial contraction

may have had an effect on surfactant release by altering
blood flow through pulmonary capillaries subserving
alveolar type II cells

(Kapanci et al. 1976).

The

contraction of interstitial cells might fold the alveolarcapillary tissue barrier into the vascular space by
pulling on the alveolar basement membrane.

Interference
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of intracapillary folds with corpuscular blood circulation
may have influenced depletion of lamellar bodies.
The absence of glycogen granules in type II cells of
these mature control and SGS cats was expected.

This

thesis research did not emphasize glycogen, but it is
interesting to note its absence with numerous reports
suggesting disappearance of these granules as maturity
approaches

(Kikkawa et al. 1968, 1971; Sorokin 1961;

Williams and Mason 1977).
The absence of the monolayer of surfactant covering
alveolar surfaces most likely reflected the destruction of
lipid by the aldehydes in the modified Karnovsky's
solution employed in tissue fixation.

Thus, information

regarding the disposition of this surfactant layer over
the alveolar surface in control versus SGS cats was not
available.

This is unfortunate because some important

functional correlates of hastened lamellar body depletion
from SGS cats may have been deduced from these results.
This represents an area for further study.
This study has provided evidence of a direct nerve
influence on release of surfactant from alveolar type II
cells.

This is the first direct evidence of depletion of

surfactant by sympathetic nerve stimulation, extending
earlier observations demonstrating the influence of
circulating catecholamines on release of surfactant from
alveolar type II cells.
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Further study is needed to determine what presently
unknown factors are responsible for surfactant function
and whether or not the proper disposition of these
components is understood well enough to permit proper
dispersion and function of replacement surfactant in vivo.
Further study using stellate ganglion stimulation
differentiating between alpha and beta adrenergic pathways
is needed to clarify specific adrenergic pathways in
surfactant release.

In addition, it remains unclear what

the actual time course may be for tne first significant
release of surface active material.

The next step is to

study this time course by using shorter intervals of
stimulation, such as 30 to 60 seconds.
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